MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
41.63
+0.98
+2.41%
After Hours: 41.44 -0.19 -0.46% 19:59 11/13 EST
OPEN
40.97
PREV CLOSE
40.65
HIGH
41.80
LOW
40.64
VOLUME
11.71M
TURNOVER
--
52 WEEK HIGH
61.21
52 WEEK LOW
34.20
MARKET CAP
184.16B
P/E (TTM)
10.78
1D
5D
1M
3M
1Y
5Y
1D
Novo Nordisk Earnings Call Signals Recovery Amid Headwinds
TipRanks · 1h ago
Novo Nordisk Says Wegovy May Help Reduce 'Food Noise' In Adults With Obesity
NASDAQ · 3h ago
Novo Nordisk Reports Strong Weight-Loss Results In Phase 3 REDEFINE 9 Trial Of CagriSema
NASDAQ · 4h ago
GLP-1s can save health system money if priced below $350 a month: analysis
Seeking Alpha · 7h ago
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
The Motley Fool · 12h ago
Novo Nordisk (NVO) Could Be 46% Undervalued After Wegovy Pill Prescription Focus
Simply Wall St · 20h ago
Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A
NASDAQ · 1d ago
Viking Therapeutics gains amid report of renewed takeover interest
Seeking Alpha · 1d ago
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.